DexCom (NasdaqGS:DXCM) experienced an 12% decline over the past week, during which the company transitioned its audit from Ernst & Young to Deloitte & Touche, and appointed Jon Coleman as Chief ...

SAN DIEGO, March 25, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer.

Dexcom (Nasdaq:DXCM) has a new chief commercial officer with significant experience at another major medtech company.

DexCom (DXCM) announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume ...

The appointment of Jon Coleman as chief commercial officer is based on a press release statement from DexCom, Inc. In other recent news, DexCom reported fourth-quarter earnings with adjusted ...

(NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom’s ...

SAN DIEGO - DexCom, Inc. (NASDAQ: DXCM), a prominent player in glucose biosensing technology with a market capitalization of $28.75 billion and an "GREAT" financial health rating according to ...